Cogent Biosciences (COGT) news
Recent news
Cogen Biosciences, Inc.: Guggenheim raises target price to $52 from $45
Guggenheim Securities has raised its price target for Cogent Biosciences, Inc. (COGT) to $52 from $45, reflecting a positive outlook on the biotechnology company’s development pipeline and therapeutic focus. Cogent Biosciences is engaged in the development of precision therapies for genetically…
AInvest Wire · Aug 11, 2026Cogen Biosciences - May offer up to $400 mln in common stock through Guggenheim Securities - SEC filing
Cogent Biosciences, Inc. (Nasdaq: COGT) has filed with the U.S. Securities and Exchange Commission (SEC) for a potential offering of up to $400 million in common stock, according to a recent filing. The offering, if executed, would be managed by Guggenheim Securities as part of the underwriting…
AInvest Wire · Aug 10, 2026Cogenics Biosciences - to submit APEX NDA in June 2026
Cogent Biosciences, Inc. (NASDAQ: COGT) announced positive top-line results from the APEX Part 2 clinical trial of bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) on December 8, 2025. Based on these findings, the company expects to submit a New Drug Application (NDA) to the…
AInvest Wire · Jun 12, 2026i Squared to buy 10 data center facilities from Cogent Fiber
Cogent Communications has entered into an agreement to sell 10 data center facilities to i Squared, a private infrastructure investment firm, as part of its ongoing strategy to monetize assets acquired from Sprint . The transaction, which is expected to generate significant proceeds, aligns with…
AInvest Wire · May 26, 2026Duquesne exits XLK, RSP, GOOGL, COGT, ENTG in 1Q: 13F
Duquesne Family Office, the investment vehicle of billionaire Stanley Druckenmiller, disclosed in its latest 13F filing on May 15, 2025, that it exited several positions in the first quarter of 2025, including XLK, RSP, GOOGL, COGT, and ENTG. The filing revealed a broader trend of portfolio…
AInvest Wire · May 15, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.